Pancreatic Cancer Research

ResearcherThe University of Texas at San Antonio Health Science CenterActive in the last 2 years

Alexander A. Parikh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2730-2354; OpenAlex author ID A5013889334. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
61
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers

Papers 17

  1. Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1002/cncr.70130↗
  2. Supportive Care Needs and Related Interventions in Patients with Pancreatic Cancer and Their Informal Caregivers: A Scoping Review. Co-author DOI 10.1007/s12029-025-01218-8↗
  3. Patient expectations about the oncologic benefit of pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.07.017↗
  4. Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected pancreatic cancer: A multi-institutional ana… Co-author DOI 10.1002/jso.27798↗
  5. Accuracy of models to prognosticate survival after surgery for pancreatic cancer in the era of neoadjuvant therapy. Co-author DOI 10.1002/jso.27287↗
  6. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancr… Co-author DOI 10.1245/s10434-022-12741-4↗
  7. Differences in receipt of multimodality therapy by race, insurance status, and socioeconomic disadvantage in patients with resected pancreatic cancer. Co-author DOI 10.1002/jso.26859↗
  8. Differential effects of the Affordable Care Act on the stage at presentation and receipt of treatment for pancreatic adenocarcinoma. Last author DOI 10.1002/jso.26984↗
  9. Opportunity Costs of Surgical Resection and Perioperative Chemotherapy for Locoregional Pancreatic Adenocarcinoma. Co-author DOI 10.1200/op.21.00311↗
  10. Thirty-day complication rates do not differ by race among patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.26383↗
  11. Actual Survival in Patients with Resected Pancreatic Cancer: How Do Real-World Data Compare with Clinical Trial Evidence? First author DOI 10.1245/s10434-021-10532-x↗
  12. Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment Co-author DOI 10.3389/fonc.2020.00553↗
  13. Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.04.013↗
  14. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-ins… Co-author DOI 10.1007/s11605-014-2567-4↗
  15. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
  16. Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. Co-author DOI 10.1111/j.1477-2574.2011.00432.x↗
  17. A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. Co-author PMID 23077684↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rebecca Anne Snyder · 8 shared papers, 2021–2025 · strength 1.51
  2. Shishir Kumar Maithel · 7 shared papers, 2014–2025 · strength 0.94
  3. Nipun B. Merchant · 9 shared papers, 2012–2025 · strength 0.89
  4. Daniel Erik Abbott · 6 shared papers, 2014–2025 · strength 0.78
  5. David A. Kooby · 7 shared papers, 2012–2025 · strength 0.77
  6. Anastasios T. Mitsakos · 4 shared papers, 2021–2022 · strength 0.73
  7. Syed Ameen Ahmad · 6 shared papers, 2012–2025 · strength 0.64
  8. Syed Nabeel Zafar · 3 shared papers, 2023–2025 · strength 0.54
  9. Scarlett B. Hao · 3 shared papers, 2022 · strength 0.54
  10. Jashodeep Datta · 3 shared papers, 2023–2025 · strength 0.51
  11. Chet W. Hammill · 3 shared papers, 2023–2025 · strength 0.50
  12. Erin M. Dickey · 2 shared papers, 2024–2025 · strength 0.37
  13. Caitlin A. Hester · 2 shared papers, 2024–2025 · strength 0.37
  14. Jashodeep Datta · 2 shared papers, 2024–2025 · strength 0.37
  15. Mary P Martos · 2 shared papers, 2024–2025 · strength 0.37
  16. Gregory C. Wilson · 3 shared papers, 2014–2024 · strength 0.34
  17. Ifeanyichukwu Chinedu Ogobuiro · 2 shared papers, 2023–2024 · strength 0.31
  18. Hong Joo Kim · 2 shared papers, 2023–2024 · strength 0.31
  19. Sharon Marie Weber · 4 shared papers, 2012–2025 · strength 0.28
  20. Charles Raben Scoggins · 4 shared papers, 2012–2025 · strength 0.28
  21. Robert C.G. Martin · 4 shared papers, 2012–2025 · strength 0.28
  22. Lixin Song · 1 shared paper, 2025 · strength 0.25
  23. Liang Fu · 1 shared paper, 2025 · strength 0.25
  24. Natasha Leigh‐Matijakovich · 1 shared paper, 2025 · strength 0.21
  25. Kawther Abdilleh · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.